Bank of America Securities Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $80.00. The company's shares closed yesterday at $34.72.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Ahmad is an analyst with an average return of -5.3% and a 43.00% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma.
In addition to Bank of America Securities, Ultragenyx Pharmaceutical also received a Buy from Morgan Stanley's Maxwell Skor in a report issued on May 8. However, on May 7, Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical (NASDAQ: RARE).
RARE market cap is currently $3.41B and has a P/E ratio of -6.02.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year. Earlier this month, Eric Crombez, the EVP and Chief Medical Officer of RARE sold 242.00 shares for a total of $8,496.62.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
43 minutes ago
- Business Insider
Coca-Cola Stock (KO) Could Benefit by Leaving Bottling Behind
Coca-Cola (KO) has slowly been moving away from bottling its own beverages, leaving that work to other companies that it sells syrup to. The company has been shifting toward this model for years now and has continued to do so with recent plant closures and layoffs. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The latest Coca-Cola layoffs include 135 jobs that were cut in Napa County, Calif. The soda maker has closed this 30-year-old plant as part of its strategic change away from bottling its own products. When Coca-Cola's plan is complete, 80% of its bottling will be outsourced to other companies. It makes sense that Coca-Cola would seek to reduce its bottling and outsource the process. Doing so makes the company more asset-light and allows it to focus on its syrup margins of 68%. For comparison, the margins for bottling are only 12%. Offloading those less profitable operations could help boost KO stock. KO Stock Analyst Coverage Analysts largely agree with this mentality, with continued praise for KO stock. That includes updates from two analysts earlier this week: Five-star Morgan Stanley analyst Dara Mohsenian reiterated a Buy rating and an $81 price target, suggesting a 12.17% upside. RBC Capital analyst Nik Modi maintained a Buy rating and a $76 price target, implying a 5.25% upside. KO stock was up 0.64% as of Tuesday morning. That builds on its 16.88% increase year-to-date and its 12.93% rally over the past 12 months. Is KO Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Coca-Cola is Strong Buy, based on 15 Buy ratings and a single Hold rating over the past three months. With that comes an average KO stock price target of $79.50, representing a potential 10.08% upside for the shares.
Hamilton Spectator
an hour ago
- Hamilton Spectator
Colliers publishes 2024 Global Sustainability Report
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ and TSX: CIGI) released its 2024 Global Sustainability Report , highlighting the firm's achievements and progress against targets established in 2021. The report also offers a first look at Colliers' refreshed sustainability strategy, Built to Last , which is based on an updated materiality assessment conducted in the first quarter of 2025. The strategy is designed to align Colliers' priorities with today's most pressing environmental, social, and governance challenges and opportunities, anchored around three core pillars: 'As a global provider of real estate, engineering and investment management services, we are in a unique position to help owner, investor and occupier clients realize their sustainability aspirations while driving the same positive impact for our own operations,' said Jay Hennick, Global Chairman & CEO of Colliers. 'I'm proud of our 2024 performance and remaining agile in our approach to what's next. I look forward to continuing our journey toward a more sustainable future though Built to Last.' Highlights from the 2024 report include: To support the next phase of our sustainability leadership, Tonya Lagrasta has been appointed Global Head of Sustainability at Colliers. A long-time sustainability leader and trusted advisor within our business, Tonya brings more than 20 years of experience across sectors including commercial real estate, retail, consumer goods, financial services, pharmaceuticals, and the public sector. In this role she will spearhead the implementation of Built to Last and drive integration of sustainability across Colliers. 'Sustainability is a reflection of our values in action, and a pathway to long-term resilience,' said Lagrasta. 'Built to Last reflects where we are today – and more importantly, where we're going. I'm energized by our people's passion and proud to help lead this next chapter of impact.' The full 2024 Global Sustainability Report is available at . About Colliers Colliers (NASDAQ, TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading platforms – Real Estate Services, Engineering, and Investment Management – we have a proven business model, an enterprising culture, and a unique partnership philosophy that drives growth and value creation. For 30 years, Colliers has consistently delivered approximately 20% compound annual returns for shareholders, fueled by visionary leadership, significant inside ownership and substantial recurring earnings. With nearly $5.0 billion in annual revenues, a team of 23,000 professionals, and more than $100 billion in assets under management, Colliers remains committed to accelerating the success of our clients, investors, and people worldwide. Learn more at , X @Colliers or LinkedIn . Media Contact Andrea Cheung Senior Manager, Global Integrated Communications +1 416 324 6402
Business Insider
an hour ago
- Business Insider
Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)
In a report released yesterday, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Insmed (INSM – Research Report), with a price target of $110.00. The company's shares closed yesterday at $90.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Suvannavejh is an analyst with an average return of -7.4% and a 41.75% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verastem, and Harmony Biosciences Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $98.36 average price target, implying an 8.17% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $94.00 price target. INSM market cap is currently $13.41B and has a P/E ratio of -11.88. Based on the recent corporate insider activity of 120 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year. Earlier this month, Orlov Nicole Schaeffer, the Chief People Strategy Officer of INSM sold 1,642.00 shares for a total of $117,403.00.
